1.Radiofrequency Ablation for Recurrent Thyroid Cancers:2025 Korean Society of Thyroid Radiology Guideline
Eun Ju HA ; Min Kyoung LEE ; Jung Hwan BAEK ; Hyun Kyung LIM ; Hye Shin AHN ; Seon Mi BAEK ; Yoon Jung CHOI ; Sae Rom CHUNG ; Ji-hoon KIM ; Jae Ho SHIN ; Ji Ye LEE ; Min Ji HONG ; Hyun Jin KIM ; Leehi JOO ; Soo Yeon HAHN ; So Lyung JUNG ; Chang Yoon LEE ; Jeong Hyun LEE ; Young Hen LEE ; Jeong Seon PARK ; Jung Hee SHIN ; Jin Yong SUNG ; Miyoung CHOI ; Dong Gyu NA ;
Korean Journal of Radiology 2025;26(1):10-28
		                        		
		                        			
		                        			 Radiofrequency ablation (RFA) is a minimally invasive treatment modality used as an alternative to surgery in patients with benign thyroid nodules, recurrent thyroid cancers (RTCs), and primary thyroid microcarcinomas. The Korean Society of Thyroid Radiology (KSThR) initially developed recommendations for the optimal use of RFA for thyroid tumors in 2009 and revised them in 2012 and 2017. As new meaningful evidence has accumulated since 2017 and in response to a growing global interest in the use of RFA for treating malignant thyroid lesions, the task force committee members of the KSThR decided to update the guidelines on the use of RFA for the management of RTCs based on a comprehensive analysis of current literature and expert consensus. 
		                        		
		                        		
		                        		
		                        	
2.Radiofrequency Ablation for Recurrent Thyroid Cancers:2025 Korean Society of Thyroid Radiology Guideline
Eun Ju HA ; Min Kyoung LEE ; Jung Hwan BAEK ; Hyun Kyung LIM ; Hye Shin AHN ; Seon Mi BAEK ; Yoon Jung CHOI ; Sae Rom CHUNG ; Ji-hoon KIM ; Jae Ho SHIN ; Ji Ye LEE ; Min Ji HONG ; Hyun Jin KIM ; Leehi JOO ; Soo Yeon HAHN ; So Lyung JUNG ; Chang Yoon LEE ; Jeong Hyun LEE ; Young Hen LEE ; Jeong Seon PARK ; Jung Hee SHIN ; Jin Yong SUNG ; Miyoung CHOI ; Dong Gyu NA ;
Korean Journal of Radiology 2025;26(1):10-28
		                        		
		                        			
		                        			 Radiofrequency ablation (RFA) is a minimally invasive treatment modality used as an alternative to surgery in patients with benign thyroid nodules, recurrent thyroid cancers (RTCs), and primary thyroid microcarcinomas. The Korean Society of Thyroid Radiology (KSThR) initially developed recommendations for the optimal use of RFA for thyroid tumors in 2009 and revised them in 2012 and 2017. As new meaningful evidence has accumulated since 2017 and in response to a growing global interest in the use of RFA for treating malignant thyroid lesions, the task force committee members of the KSThR decided to update the guidelines on the use of RFA for the management of RTCs based on a comprehensive analysis of current literature and expert consensus. 
		                        		
		                        		
		                        		
		                        	
3.Radiofrequency Ablation for Recurrent Thyroid Cancers:2025 Korean Society of Thyroid Radiology Guideline
Eun Ju HA ; Min Kyoung LEE ; Jung Hwan BAEK ; Hyun Kyung LIM ; Hye Shin AHN ; Seon Mi BAEK ; Yoon Jung CHOI ; Sae Rom CHUNG ; Ji-hoon KIM ; Jae Ho SHIN ; Ji Ye LEE ; Min Ji HONG ; Hyun Jin KIM ; Leehi JOO ; Soo Yeon HAHN ; So Lyung JUNG ; Chang Yoon LEE ; Jeong Hyun LEE ; Young Hen LEE ; Jeong Seon PARK ; Jung Hee SHIN ; Jin Yong SUNG ; Miyoung CHOI ; Dong Gyu NA ;
Korean Journal of Radiology 2025;26(1):10-28
		                        		
		                        			
		                        			 Radiofrequency ablation (RFA) is a minimally invasive treatment modality used as an alternative to surgery in patients with benign thyroid nodules, recurrent thyroid cancers (RTCs), and primary thyroid microcarcinomas. The Korean Society of Thyroid Radiology (KSThR) initially developed recommendations for the optimal use of RFA for thyroid tumors in 2009 and revised them in 2012 and 2017. As new meaningful evidence has accumulated since 2017 and in response to a growing global interest in the use of RFA for treating malignant thyroid lesions, the task force committee members of the KSThR decided to update the guidelines on the use of RFA for the management of RTCs based on a comprehensive analysis of current literature and expert consensus. 
		                        		
		                        		
		                        		
		                        	
4.Radiofrequency Ablation for Recurrent Thyroid Cancers:2025 Korean Society of Thyroid Radiology Guideline
Eun Ju HA ; Min Kyoung LEE ; Jung Hwan BAEK ; Hyun Kyung LIM ; Hye Shin AHN ; Seon Mi BAEK ; Yoon Jung CHOI ; Sae Rom CHUNG ; Ji-hoon KIM ; Jae Ho SHIN ; Ji Ye LEE ; Min Ji HONG ; Hyun Jin KIM ; Leehi JOO ; Soo Yeon HAHN ; So Lyung JUNG ; Chang Yoon LEE ; Jeong Hyun LEE ; Young Hen LEE ; Jeong Seon PARK ; Jung Hee SHIN ; Jin Yong SUNG ; Miyoung CHOI ; Dong Gyu NA ;
Korean Journal of Radiology 2025;26(1):10-28
		                        		
		                        			
		                        			 Radiofrequency ablation (RFA) is a minimally invasive treatment modality used as an alternative to surgery in patients with benign thyroid nodules, recurrent thyroid cancers (RTCs), and primary thyroid microcarcinomas. The Korean Society of Thyroid Radiology (KSThR) initially developed recommendations for the optimal use of RFA for thyroid tumors in 2009 and revised them in 2012 and 2017. As new meaningful evidence has accumulated since 2017 and in response to a growing global interest in the use of RFA for treating malignant thyroid lesions, the task force committee members of the KSThR decided to update the guidelines on the use of RFA for the management of RTCs based on a comprehensive analysis of current literature and expert consensus. 
		                        		
		                        		
		                        		
		                        	
5.Radiofrequency Ablation for Recurrent Thyroid Cancers:2025 Korean Society of Thyroid Radiology Guideline
Eun Ju HA ; Min Kyoung LEE ; Jung Hwan BAEK ; Hyun Kyung LIM ; Hye Shin AHN ; Seon Mi BAEK ; Yoon Jung CHOI ; Sae Rom CHUNG ; Ji-hoon KIM ; Jae Ho SHIN ; Ji Ye LEE ; Min Ji HONG ; Hyun Jin KIM ; Leehi JOO ; Soo Yeon HAHN ; So Lyung JUNG ; Chang Yoon LEE ; Jeong Hyun LEE ; Young Hen LEE ; Jeong Seon PARK ; Jung Hee SHIN ; Jin Yong SUNG ; Miyoung CHOI ; Dong Gyu NA ;
Korean Journal of Radiology 2025;26(1):10-28
		                        		
		                        			
		                        			 Radiofrequency ablation (RFA) is a minimally invasive treatment modality used as an alternative to surgery in patients with benign thyroid nodules, recurrent thyroid cancers (RTCs), and primary thyroid microcarcinomas. The Korean Society of Thyroid Radiology (KSThR) initially developed recommendations for the optimal use of RFA for thyroid tumors in 2009 and revised them in 2012 and 2017. As new meaningful evidence has accumulated since 2017 and in response to a growing global interest in the use of RFA for treating malignant thyroid lesions, the task force committee members of the KSThR decided to update the guidelines on the use of RFA for the management of RTCs based on a comprehensive analysis of current literature and expert consensus. 
		                        		
		                        		
		                        		
		                        	
6.Aster glehni Ethanol Extract Inhibits Inflammatory Responses Regulating Skin Barrier Molecules in Human Keratinocytes
Tae-Young GIL ; Hyo-Jung KIM ; Hye-Min KIM ; Ha-Yeon SIM ; Woolim CHOI ; Bum Soo LEE ; Ki Hyun KIM ; Hyo-Jin AN
Natural Product Sciences 2024;30(4):262-267
		                        		
		                        			
		                        			   Prolonged  skin  inflammation  is  caused  by  disrupted  skin  barrier  resulting  in  chronic  inflammatory diseases  such  as  atopic  dermatitis.  As  a  potent  natural  product  with  anti-inflammatory  property,  Aster glehni (A. glehni)  is  a  traditional  edible  herb  and  has  been  used  to  treat  diabetes  or  colitis-associated  colon  cancer.  In present  study,  we  figured  out  an  additional  effect  of  A. glehni  ethanol  extract  (AGE)  in  pro-inflammatory cytokines-stimulated  human  keratinocytes.  Mixture  of  tumor  necrosis  factor-alpha  (TNF-α)  and  interferongamma  (IFN-γ)  was  used  to  induce  inflammatory  responses  in  the  HaCaT  keratinocytes.  AGE  suppressed activation of ERK mitogen-activated protein kinase, nuclear factor (NF)-κB, and signal transducer and activator of  transcription  1  and  3  (STAT1  and  STAT3).  The  treatment  of  AGE  inhibited  mRNA  expressions  of  proinflammatory  cytokines  in  TNF-α  and  IFN-γ-stimulated  HaCaT  cells.  Also,  AGE  induced  up-regulated expressions of skin barrier molecules like filaggrin, loricrin, or ZO-1. We evaluated the effects of AGE on protein or  mRNA  expression  levels  using  western  blot  or  qRT-PCR,  respectively.  Taken  together,  these  results  suggest that  the  treatment  of  AGE  exerts  anti-inflammatory  effect  on  keratinocytes  through  suppressing  inflammatory signaling pathways and up-regulating skin molecules in HaCaT keratinocytes. 
		                        		
		                        		
		                        		
		                        	
7.Enhancing the Survival of Congenital Diaphragmatic Hernia:Quality Improvement Initiative With a Multidisciplinary Extracorporeal Membrane Oxygenation Team Approach
Byong Sop LEE ; Euiseok JUNG ; Heeyoung KIM ; Soo Hyun KIM ; Jiyoon JEONG ; Ha Na LEE ; Hyunhee KWON ; Jung-Man NAMGOONG ; Dae Yeon KIM
Journal of Korean Medical Science 2024;39(48):e300-
		                        		
		                        			 Background:
		                        			Extracorporeal membrane oxygenation (ECMO) is the only treatment option that can stabilize patients with congenital diaphragmatic hernia (CDH) with severe pulmonary hypertension. This study assessed the effects of a multidisciplinary ECMO team approach (META) as part of a quality improvement initiative aimed at enhancing the survival rates of neonates with CDH. 
		                        		
		                        			Methods:
		                        			The medical records of infants with CDH treated at a tertiary center were retrospectively reviewed. Patients were categorized into two groups based on META implementation. The META group (P2) were given key interventions, including on-site ECMO management within the neonatal intensive care unit (NICU), use of venoarterial modality, ECMO indication as a priority even before the use of inhaled nitric oxide, and preplanned surgery following ECMO discontinuation. These approaches were compared with standard protocols in the pre-META group (P1) to assess their effects on clinical outcomes, particularly in-hospital mortality. 
		                        		
		                        			Results:
		                        			Over a 16-year period, 322 patients were included. P2 had a significantly higher incidence of non-isolated CDH and higher rate of cesarean section compared with P1.Moreover, P2 had delayed time to surgical repair (9.4 ± 8.0 days) compared with P1 (6.7 ± 7.3 days) (P = 0.004). The overall survival rate at NICU discharge was 72.7%, with a significant improvement from P1 (66.3%, 132/199) to P2 (82.9%, 102/123) (P = 0.001). Among the 68 patients who received ECMO, P2 had significantly lower baseline oxygenation index and serum lactate levels before ECMO cannulation than P1. The survival rate of patients who received ECMO also remarkably improved from P1 (21.1%, 8/38) to P2 (56.7%, 17/30).Subgroups who could be weaned from ECMO before 2 weeks after cannulation showed the best survival rate. 
		                        		
		                        			Conclusion
		                        			META significantly improved the survival rate of newborn infants with CDH.Further interventions, including prenatal intervention and novel ECMO strategies, may help improve the clinical outcomes and quality of life. 
		                        		
		                        		
		                        		
		                        	
8.Aster glehni Ethanol Extract Inhibits Inflammatory Responses Regulating Skin Barrier Molecules in Human Keratinocytes
Tae-Young GIL ; Hyo-Jung KIM ; Hye-Min KIM ; Ha-Yeon SIM ; Woolim CHOI ; Bum Soo LEE ; Ki Hyun KIM ; Hyo-Jin AN
Natural Product Sciences 2024;30(4):262-267
		                        		
		                        			
		                        			   Prolonged  skin  inflammation  is  caused  by  disrupted  skin  barrier  resulting  in  chronic  inflammatory diseases  such  as  atopic  dermatitis.  As  a  potent  natural  product  with  anti-inflammatory  property,  Aster glehni (A. glehni)  is  a  traditional  edible  herb  and  has  been  used  to  treat  diabetes  or  colitis-associated  colon  cancer.  In present  study,  we  figured  out  an  additional  effect  of  A. glehni  ethanol  extract  (AGE)  in  pro-inflammatory cytokines-stimulated  human  keratinocytes.  Mixture  of  tumor  necrosis  factor-alpha  (TNF-α)  and  interferongamma  (IFN-γ)  was  used  to  induce  inflammatory  responses  in  the  HaCaT  keratinocytes.  AGE  suppressed activation of ERK mitogen-activated protein kinase, nuclear factor (NF)-κB, and signal transducer and activator of  transcription  1  and  3  (STAT1  and  STAT3).  The  treatment  of  AGE  inhibited  mRNA  expressions  of  proinflammatory  cytokines  in  TNF-α  and  IFN-γ-stimulated  HaCaT  cells.  Also,  AGE  induced  up-regulated expressions of skin barrier molecules like filaggrin, loricrin, or ZO-1. We evaluated the effects of AGE on protein or  mRNA  expression  levels  using  western  blot  or  qRT-PCR,  respectively.  Taken  together,  these  results  suggest that  the  treatment  of  AGE  exerts  anti-inflammatory  effect  on  keratinocytes  through  suppressing  inflammatory signaling pathways and up-regulating skin molecules in HaCaT keratinocytes. 
		                        		
		                        		
		                        		
		                        	
		                				9. Local Governance for COVID-19Response of Daegu Metropolitan City 
		                			
		                			Kyeong-Soo LEE ; Jung Jeung LEE ; Keon-Yeop KIM ; Jong-Yeon KIM ; Tae-Yoon HWANG ; Nam-Soo HONG ; Jun Hyun HWANG ; Jaeyoung HA
Journal of Agricultural Medicine & Community Health 2024;49(1):13-36
		                        		
		                        			 Objectives:
		                        			The purpose of this field case report is 1) to analyze the community's strategy and performance in responding to infectious diseases through the case of COVID-19 infectious disease crisis response of Daegu Metropolitan City, and 2) to interpret this case using governance theory and infectious disease response governance framework. and 3) to propose a strategic model to prepare for future infectious disease outbreaks of the community. 
		                        		
		                        			Methods:
		                        			Cases of Daegu Metropolitan City's infectious disease crisis response were analyzed through researchers' participatory observations. And review of OVID-19 White Paper of Daegu Metropolitan City, Daegu Medical Association's COVID-19 White Paper, and literature review of domestic and international governance, and administrative documents. 
		                        		
		                        			Results:
		                        			Through the researcher's participatory observation and literature review, 1) establishment of leadership and response system to respond to the infectious disease crisis in Daegu Metropolitan City, 2) citizen’s participation and communication strategy through the pan-citizen response committee, 3) cooperation between Daegu Metropolitan City and governance of public-private medical facilities, 4) decision-making and crisis response through participation and communication between the Daegu Metropolitan City Medical Association, Medi-City Daegu Council, and medical experts of private sector, 5) symptom monitoring and patient triage strategies and treatment response for confirmed infectious disease patients by member of Daegu Medical Association, 6) strategies and implications for establishing and utilizing a local infectious disease crisis response information system were derived. 
		                        		
		                        			Conclusions
		                        			The results of the study empirically demonstrate that collaborative governance of the community through the participation of citizens, private sector experts, and community medical facilities is a key element for effective response to infectious disease crises. 
		                        		
		                        		
		                        		
		                        	
10.Toxicological properties of Technekitty injection (Tc-99m) in diagnosing feline hyperthyroidism
Jae Cheong LIM ; So-Young LEE ; Eun Ha CHO ; Yu Mi JUNG ; Ki Hwan PARK ; Young Uk PARK ; Sung Soo NAM ; Tae Hoon LEE ; Jae Won LEE ; Yiseul CHOI ; Inki LEE ; Yeon CHAE ; Byeong-Teck KANG
Journal of Biomedical and Translational Research 2024;25(4):201-210
		                        		
		                        			
		                        			 Following the previous study, which investigated the pharmacological properties of the Technekitty injection (Tc-99m), the toxicity of a single intravenous administration of the Technekittyinjection (Tc-99m) and the side effects that may occur at the diagnostic dose were confirmed.The Technekitty injection (Tc-99m) was administered intravenously once at a dose of 0, 0.67, 2.0, and 6.0 mCi/kg to 5 male and female rats per group. Mortality, general symptom obser-vation, and weight measurement were performed for 2 weeks, followed by observation of autopsy findings. There were no deaths, and no statistically significant weight change was observed. No abnormal systemic signs related to the Technekitty injection (Tc-99m) were observed. These results confirmed that Technekitty injection (Tc-99m) can be safely admin-istered intravenously at doses up to 6.0 mCi/kg. Additionally, technetium-99m at an average dose of 2 mCi (74 MBq) has been verified as a diagnostic dose without adverse effects, al-lowing the Technekitty injection (Tc-99m) to be used safely without side effects at this dosage.This study demonstrates that the Technekitty injection (Tc-99m) has a wide safety margin, supporting its potential for clinical application. Moreover, these findings align with the nonclin-ical safety standards for radiopharmaceuticals, reinforcing its utility in veterinary medicine.The Technekitty injection (Tc-99m) is expected to be applicable for clinical diagnosis as a vet-erinary drug in Korea. 
		                        		
		                        		
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail